Advertisement
Led by seasoned pharmaceutical executives, PMI is the first and fastest-growing pre-disease therapeutics company in the world. For the first time, PMIintroduces evidence-based, all-natural, proprietary combination therapiesexclusively to physicians, just like new prescription drugs are introduced,with fully trained sales professionals, credible peer-reviewed data onefficacy and safety and product training. PMI's new approach is to givephysicians and patients effective and safe therapeutic options for managing avariety of pre-disease states before they become irreversible in the hopes ofdramatically changing the course of their disease.
Advertisement
Currently, with no known prescription products indicated for pre-diseaseusage, PMI has the opportunity to define its pre-disease space with its twice-daily formulations. While this market has always existed, there are nowdefined biomarkers for common chronic diseases, which are clear indicators forthe impending full-blown disease. The marketplace of patients "at-risk" fordeveloping a disease is typically five to six times larger than the market forpatients who already have disease.
Launched products include PreLipid(TM) and PreLipid Plus(TM) thateffectively lower cholesterol and protect cardiovascular health, andPreCrea(TM), which lowers blood sugar levels and restores balance in thepancreas. PMI also recently introduced PreMenora(TM) and PreMenora Plus(TM)for perimenopausal symptoms and bone health. Other pipeline products willinclude clinically proven plant-based, proprietary formulations to treatsymptoms of arthritis, benign prostate enlargement, hemorrhoids, insomnia,early memory loss and a formulation to boost immunity against infections.
"We at PreEmptive Meds are delighted to have the opportunity to offereffective and safe, all natural, proprietary products to physicians for theirpatients, targeted exclusively for pre-disease," stated Chuck Blitzer,PreEmptive Med's Chief Executive Officer. We believe pre-disease is asignificant area of medicine where prescription drugs play little if any roleand where PreEmptive Med's proprietary products can make an importanttherapeutic contribution. "
PMI only promotes its products to physicians as the Company believes thatonly physicians should make decisions about patients' health and therapeuticoptions as only physicians are knowledgeable to review the clinicalinformation on the products and recommend them appropriately. The scientificbases of PMI's plant-based products are rooted in the traditional systems ofmedicine used for centuries in Asia, South America, Europe and the US. Todaythere is credible evidence from controlled studies of efficacy and safety onplant based ingredients being reported by researchers from around the world.In their proprietary combination-therapy formulations, the Company has for thefirst time successfully integrated ingredients based on evidence from varioustraditional systems.
"Most chronic diseases begin and progress because multiple patho-physiologies occur in the body" says Dr. Michael Davidson, Executive MedicalDirector of Radiant Research in Chicago, IL, a well known researcher and aworld expert on lipids and preventive cardiology. "So in order to preemptprogression of disease, one must have effective combination therapies thattarget the various concurrent abnormalities and physicians need to haveoptions to effectively treat disease in their patients as generally no singleagent is sufficient." Dr. Davidson, concludes, "PMI's combinations of plant-based ingredients are designed to target elevated cholesterol levels, one ofthe
